Services
Imexpharm JSC organized an investor and analyst conference to announce its business results for the first half of 2024. Source: Imexpharm.
|
In the first half of 2024, Imexpharm continued to solidify its leading position in the production and distribution of high-quality antibiotics, as well as in the ETC channel. Speaking at the conference, Mr. Nguyen An Duy, Deputy CEO of Finance, shared: “We are on a strong growth trajectory, and the second half of 2024 will be even more impressive, ensuring that we achieve our set goals. Imexpharm remains innovative and agile in our business operations, with our chartered capital expected to be the largest among Vietnamese pharmaceutical companies. The first six months of 2024 have proven Imexpharm’s resilience as we maintained stable operations amidst a volatile market, while also preparing for robust growth in both domestic and international markets.”
Imexpharm’s robust growth in the first half of 2024 is evident through impressive figures: revenue reached VND 1,008 billion, a 10% increase compared to the same period last year; sales revenue in the ETC channel during the first half increased by 33% year-on-year; sales revenue through the chain channel rose by 141% compared to the first half of last year; profit before tax (PBT) and EBITDA were recorded at VND 161 billion and VND 215 billion, respectively, maintaining a stable EBITDA margin of 21%. Notably, the company’s market capitalization as of the closing price on July 31 reached more than VND 6,300 billion, a 60% increase since the beginning of the year.
Mr. Nguyen An Duy, Deputy CEO of Finance, sharing at the conference. Source: Imexpharm.
|
In terms of business operations during the first half of 2024, Imexpharm was active in research and development (R&D) initiatives and business efficiency improvement measures. Notable activities include: launching 10 new SKUs and currently working on 93 R&D projects; signing a strategic cooperation agreement with Genuone Sciences Inc.; increasing production for high-value-segment drugs at IMP2, IMP3, and IMP4 factories; and initiating a project to upgrade the enterprise resource planning software from SAP ECC to SAP S/4HANA.
To strengthen its chartered capital and support its growth plans and business expansion over the next 3-5 years, Imexpharm sought shareholder approval for a 1:1 bonus share issuance. After obtaining shareholder approval and SSC approval, the bonus share issuance to increase chartered capital is expected to be completed in the fourth quarter of 2024. Consequently, Imexpharm will become the Vietnamese pharmaceutical company with the highest chartered capital, further solidifying its leading position and competitiveness in the market.
Research and development of products at Imexpharm’s EU-GMP-standard factory. Source: Imexpharm.
|
The conference was co-chaired by Mr. Le Van Nha Phuong, Deputy CEO of Production at Imexpharm. With favorable policy frameworks and a strategic focus on expanding distribution channels in the North and international markets, the company’s management shared that they have already initiated the IMP5 factory project in the past few months to ensure the company’s growth strategy for the coming years.
Tracodi (TCD) earns 163 billion VND profit in 2023
Throughout the year 2023, Tracodi achieved a consolidated net revenue of VND 1,784.5 billion and a post-tax profit of VND 163.3 billion.
Building Peace earns over one hundred billion in Q4 2023, breaks four consecutive quarters of losses, HBC stock soars in January 30th session.
As of December 31, 2023, Hòa Bình Construction continues to incur a cumulative loss of nearly 2,900 billion Vietnamese dong.
Novaland reports over VND 1,600 billion in profit for Q4/2023, bond debt reduced by VND 6,000 billion in one year.
In 2023, Novaland achieved a profit of over 800 billion VND, in contrast to the first half of the year when the company incurred a loss of over 1,000 billion VND.
